13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue
Key Takeaways
- Emetic risk classification dictates antiemetic regimens: High Emetic Risk Chemotherapy (HEC, >90% emetogenicity including cisplatin >=50 mg/m2, cyclophosphamide >=1500 mg/m2, dacarbazine, and all anthracycline + cyclophosphamide [AC] combinations in breast cancer) mandates a 4-drug prophylactic regimen: Olanzapine + NK1 receptor antagonist (RA) + 5-HT3 RA + Dexamethasone.
- Moderate Emetic Risk Chemotherapy (MEC, 30–90% risk, e.g., carboplatin AUC >=4, oxaliplatin, irinotecan, cyclophosphamide <1500 mg/m2) requires a 2-to-3 drug regimen; carboplatin AUC >=4 specifically warrants a 3-drug regimen including an NK1 RA + 5-HT3 RA + Dexamethasone.
- Neurokinin-1 (NK1) receptor antagonists demonstrate critical pharmacokinetic interactions: oral aprepitant and IV fosaprepitant are moderate CYP3A4 inhibitors, requiring a 40–50% dose reduction of co-administered dexamethasone (e.g., from 20 mg to 12 mg on Day 1, and 8 mg daily on Days 2–4), whereas rolapitant (Varubi) inhibits CYP2D6 (contraindicated with thioridazine) and does NOT require dexamethasone dose reduction.
- Second-generation 5-HT3 antagonist palonosetron features a prolonged terminal elimination half-life (~40 hours) and allosteric receptor binding that induces receptor internalization and inhibits 5-HT3/NK1 receptor crosstalk, conferring superior control of delayed CINV compared to first-generation 5-HT3 antagonists (ondansetron, granisetron).
- Breakthrough CINV management necessitates adding an agent from an unutilized pharmacologic class with a distinct mechanism of action (e.g., olanzapine 5–10 mg PO daily if not used frontline, dopamine antagonists like prochlorperazine or promethazine, metoclopramide, cannabinoids, or haloperidol) rather than escalating the dose of the failing baseline antiemetic.
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue
Chemotherapy-Induced Nausea and Vomiting (CINV) remains one of the most feared and debilitating toxicities of cancer pharmacotherapy. Uncontrolled emesis precipitates severe dehydration, electrolyte derangements (hypokalemia, hypochloremic metabolic alkalosis), prerenal azotemia, esophageal tears (Mallory-Weiss syndrome), nutritional deterioration, functional decline, and compromised antineoplastic adherence leading to suboptimal disease control.
Over the past two decades, clinical oncology pharmacy research has revolutionized CINV management. The introduction of second-generation 5-hydroxytryptamine-3 (5-HT3) receptor antagonists, neurokinin-1 (NK1) receptor antagonists, and the integration of atypical antipsychotics (olanzapine) into four-drug prophylactic regimens have elevated complete response rates (no emesis and no rescue antiemetics) to over 85–90% even with highly emetogenic regimens.
Board-certified oncology pharmacists (BCOP) are responsible for risk-stratifying antineoplastic regimens, designing personalized multi-target prophylactic regimens, adjusting corticosteroid dosing for cytochrome P450 interactions, mitigating QTc prolongation risks, and establishing evidence-based breakthrough algorithms.
1. Neurobiology & Temporal Phases of CINV
Emesis is coordinated by the vomiting center in the lateral reticular formation of the medulla oblongata. The vomiting center receives afferent inputs from four major anatomical pathways:
- The Chemoreceptor Trigger Zone (CTZ / Area Postrema): Located at the caudal end of the fourth ventricle. Because the area postrema lacks a fully intact blood-brain barrier, it directly samples emetogenic toxins, chemotherapy agents, and metabolites circulating in systemic blood and cerebrospinal fluid.
- The Gastrointestinal Tract (Enterochromaffin Cells & Vagal Afferents): Cytotoxic agents cause cellular damage and mucosal oxidative stress in the gut, triggering enterochromaffin cells to release large amounts of serotonin (5-HT). Serotonin binds 5-HT3 receptors on vagal afferent nerve endings, transmitting impulses directly to the solitary tract nucleus (NTS) and the CTZ.
- The Vestibular System: Mediated by histamine H1 and muscarinic M1 receptors (motion-associated emesis).
- Cerebral Cortex and Limbic System: Mediates anticipatory nausea and vomiting triggered by conditioned cognitive, visual, or olfactory cues (anxiety, memory of prior emesis).
+---------------------------------------------------------------------------------------------------+
| NEUROCHEMICAL PATHWAYS OF CINV |
| |
| [CYTOTOXIC CHEMOTHERAPY] |
| | |
| +---------------------------------------+ |
| | (Bloodstream / CSF Circulation) | (Mucosal Damage / Enterochromaffin Cells) |
| v v |
| [AREA POSTREMA / CTZ] [MASSIVE SEROTONIN RELEASE] |
| (Lacks Blood-Brain Barrier) | |
| - Dopamine (D2) Receptors v |
| - Substance P / NK1 Receptors [5-HT3 RECEPTORS ON VAGAL AFFERENTS] |
| - Serotonin (5-HT3) Receptors | |
| | | (Vagal Impulses via Cranial Nerve X) |
| +-------------------+-------------------+ |
| | |
| v |
| [NUCLEUS TRACTUS SOLITARIUS (NTS)] |
| - High density of NK1 and 5-HT3 Receptors |
| | |
| v |
| [MEDULLARY VOMITING CENTER] |
| | |
| v (Efferent Motor Signals via Phrenic & Vagus Nerves) |
| [SOMATIC & VISCERAL EFFECTORS] ==> Diaphragm, Abdominal Wall, Stomach, Esophagus |
| ==> RETCHING AND EMESIS |
+---------------------------------------------------------------------------------------------------+
Clinical Classification & Temporal Phases of CINV
| CINV Type | Onset & Peak Timing | Primary Neurotransmitter / Pathway | Hallmark Chemotherapy Triggers | Primary Prophylactic / Management Strategy |
|---|---|---|---|---|
| Acute CINV | Onset: 1–2 hours post-chemo<br>Peak: 5–6 hours<br>Duration: Up to 24 hours | Serotonin (5-HT) acting on peripheral 5-HT3 receptors on vagal afferents | Cisplatin, Carboplatin, Anthracyclines, Cyclophosphamide, Dacarbazine | 5-HT3 Receptor Antagonists (Palonosetron, Ondansetron) + Dexamethasone |
| Delayed CINV | Onset: >24 hours post-chemo<br>Peak: 48–72 hours<br>Duration: Days 2 to 5 (up to 120h) | Substance P binding to central Neurokinin-1 (NK1) receptors in the NTS / CTZ | Cisplatin (>=50 mg/m2), Carboplatin (AUC >=4), Cyclophosphamide, Doxorubicin | NK1 Receptor Antagonists (Aprepitant, Fosaprepitant, Netupitant) + Olanzapine + Dexamethasone |
| Anticipatory CINV | Prior to chemotherapy administration (conditioned response) | Conditioned Pavlovian reflex; Cerebral cortex & limbic system (GABA deficiency, anxiety) | Prior poorly controlled CINV in preceding cycles; high baseline anxiety | Benzodiazepines (Lorazepam 0.5–2 mg PO/IV night before and 1h prior to chemo) + Behavioral desensitization |
| Breakthrough CINV | Occurs anytime despite optimal guideline-directed prophylaxis | Multi-pathway activation (Dopaminergic, Histaminergic, Muscarinic, Serotonergic) | Inadequate initial antiemetic intensity or refractory biological subtype | Add an agent from an unutilized pharmacologic class (e.g., Olanzapine, Prochlorperazine, Promethazine, Metoclopramide) |
| Refractory CINV | Occurs in subsequent treatment cycles after failure of prophylaxis and rescue | Intrinsic neurochemical resistance; upregulation of alternate pathways | Step-up baseline prophylaxis for subsequent cycles (e.g., upgrade MEC to HEC 4-drug regimen) |
2. Emetogenic Risk Stratification of Antineoplastic Regimens
Emetogenic potential is classified by the percentage of patients expected to experience acute emesis in the absence of effective antiemetic prophylaxis (ASCO, NCCN, MASCC-ESMO 2024–2026 Consensus Guidelines).
+---------------------------------------------------------------------------------------------------+
| ANTINEOPLASTIC EMETOGENIC POTENTIAL TIERS |
| |
| [HIGH EMETIC RISK (HEC)]: > 90% Frequency of Emesis without Prophylaxis |
| - Cisplatin (>= 50 mg/m2) |
| - Anthracycline + Cyclophosphamide (AC) combinations in any solid tumor (e.g., Breast Cancer) |
| - Cyclophosphamide (>= 1500 mg/m2) |
| - Carmustine (BCNU > 250 mg/m2) |
| - Dacarbazine (DTIC) |
| - Mechlorethamine (Nitrogen Mustard) |
| - Streptozocin |
| - High-Dose Melphalan (>= 140 mg/m2; HSCT conditioning) |
| - High-Dose Cytarabine (HiDAC > 1 g/m2 per dose) |
| |
| [MODERATE EMETIC RISK (MEC)]: 30% to 90% Frequency of Emesis without Prophylaxis |
| - **Carboplatin (AUC >= 4)** (Special risk category: warrants 3-drug NK1 RA regimen!) |
| - Cisplatin (< 50 mg/m2) |
| - Oxaliplatin (> 75 mg/m2) |
| - Irinotecan (all doses) |
| - Cyclophosphamide (< 1500 mg/m2) |
| - Doxorubicin (< 60 mg/m2), Epirubicin (< 90 mg/m2), Idarubicin, Daunorubicin |
| - Ifosfamide (>= 2 g/m2/dose) |
| - Bendamustine (>= 90 mg/m2) |
| - Clofarabine, Romidepsin, Trabectedin, Temozolomide (oral > 75 mg/m2/day) |
| |
| [LOW EMETIC RISK]: 10% to 30% Frequency of Emesis without Prophylaxis |
| - Paclitaxel, Docetaxel, Cabazitaxel, Nab-Paclitaxel |
| - 5-Fluorouracil (5-FU), Capecitabine, Gemcitabine, Pemetrexed, Methotrexate (< 50 mg/m2) |
| - Etoposide, Topotecan, Vinorelbine, Mitoxantrone, Panitumumab, Cetuximab |
| |
| [MINIMAL EMETIC RISK]: < 10% Frequency of Emesis without Prophylaxis |
| - Monoclonal Antibodies (Trastuzumab, Pertuzumab, Bevacizumab, Rituximab, Nivolumab, Pembro) |
| - Vincristine, Vinblastine |
| - Bleomycin, Fludarabine, Cladribine, 2-Chlorodeoxyadenosine |
+---------------------------------------------------------------------------------------------------+
Patient-Specific Risk Modifiers
In addition to the inherent emetogenicity of the drug, clinical oncology pharmacists must evaluate independent patient-specific risk factors that lower the emetic threshold:
- Risk-Increasing Factors: Female sex, younger age (<50 years), history of motion sickness, history of pregnancy-related nausea/morning sickness, low or absent lifetime alcohol consumption (<5 drinks/week), high baseline anxiety, impaired performance status.
- Risk-Decreasing Factors: Chronic heavy alcohol consumption (induces tolerance/downregulation of central emetic receptors).
3. Antiemetic Pharmacology, Mechanisms & Drug Interactions
5-HT3 Receptor Antagonists
5-HT3 antagonists competitively block serotonin receptors in the gastrointestinal tract (vagal afferents) and central CTZ. They are highly effective for acute CINV but have modest activity against delayed emesis when used as monotherapy.
+---------------------------------------------------------------------------------------------------+
| FIRST-GENERATION vs. SECOND-GENERATION 5-HT3 ANTAGONISTS |
| |
| [FIRST-GENERATION: Ondansetron, Granisetron, Dolasetron] |
| - Binding: Simple competitive, reversible antagonism. |
| - Elimination Half-Life: Short (Ondansetron: 3-5 hours; Granisetron: 8-11 hours). |
| - Delayed CINV Efficacy: Poor as single agents; require redosing for multi-day chemotherapy. |
| - Cardiac Safety Warning: **Dose-dependent QTc prolongation** & risk of Torsades de Pointes. |
| * **FDA Black Box / Safety Mandate:** Maximum single IV dose of Ondansetron is **16 mg**. |
| * (Historical 32 mg single IV dose was withdrawn due to fatal arrhythmias!). |
| * Oral ondansetron 24 mg single dose remains approved (slower absorption/blunted peak level). |
| * IV Dolasetron is CONTRAINDICATED for CINV due to severe QTc/PR interval prolongation. |
| |
| [SECOND-GENERATION: Palonosetron (Aloxi)] |
| - Binding: **Allosteric binding with high affinity (pKi 10.4; ~100-fold higher than ondansetron)| |
| and positive cooperativity**, triggering **persistent 5-HT3 receptor internalization**! |
| - Receptor Cross-Talk Inhibition: Inhibits downstream 5-HT3 and NK1 receptor cross-talk. |
| - Elimination Half-Life: **Prolonged (~40 hours)**. |
| - Single Dose (0.25 mg IV or 0.5 mg PO Day 1) covers BOTH Acute AND Delayed CINV! |
| - Cardiac Safety: No clinically significant effect on QTc or PR intervals. |
+---------------------------------------------------------------------------------------------------+
Neurokinin-1 (NK1) Receptor Antagonists
Substance P is a mammalian neuropeptide that binds central NK1 receptors in the nucleus tractus solitarius to mediate delayed emesis. NK1 receptor antagonists cross the blood-brain barrier to block Substance P binding.
+---------------------------------------------------------------------------------------------------+
| NK1 RECEPTOR ANTAGONIST COMPARATIVE PHARMACOLOGY |
| |
| 1. APREPITANT (Emend - Oral): |
| - Dosing: 3-Day Regimen: **125 mg PO Day 1**, then **80 mg PO daily on Days 2 and 3**. |
| - Alternate: 130 mg emulsion single-dose IV infusion on Day 1. |
| - Cytochrome Interaction: **Moderate CYP3A4 inhibitor** (dose-dependent) and CYP2C9 inducer.|
| - PHARMACY MANDATE: **Reduce co-administered oral Dexamethasone dose by ~40-50%** |
| (e.g., Day 1: 20 mg -> 12 mg; Days 2-4: 16 mg -> 8 mg daily). |
| |
| 2. FOSAPREPITANT (Emend - IV Prodrug): |
| - Dosing: **150 mg IV infusion over 20-30 minutes on Day 1 only** (rapidly converted to |
| aprepitant within 30 minutes by ubiquitous esterases). |
| - Infusion Toxicity: High rate of infusion-site reactions / chemical phlebitis (~3-5%) due |
| to formulation excipient (polysorbate 80). Administer via dedicated line or central line. |
| - Drug Interaction: Moderate CYP3A4 inhibitor -> Reduce Dexamethasone by 40-50%. |
| |
| 3. NETUPITANT / PALONOSETRON (NEPA / Akynzeo): |
| - Dosing: Oral: Netupitant 300 mg / Palonosetron 0.5 mg PO Day 1 (60 min pre-chemo). |
| IV: Fosnetupitant 235 mg / Palonosetron 0.25 mg IV Day 1. |
| - Mechanism: Dual NK1 / 5-HT3 antagonism; synergistically inhibits substance P signaling. |
| - Drug Interaction: Netupitant is a moderate CYP3A4 inhibitor -> Reduce Dexamethasone to 12 mg.|
| |
| 4. ROLAPITANT (Varubi - Oral): |
| - Dosing: **180 mg PO single dose on Day 1 only** (administer every >=14 days). |
| - Elimination Half-Life: Extremely prolonged (**~180 hours / 7 days**). |
| - CYP Interaction: **NOT a CYP3A4 inhibitor/inducer** -> **NO DEXAMETHASONE DOSE REDUCTION!** |
| - Critical Warning: **Moderate CYP2D6 inhibitor** lasting >7 days. CONTRAINDICATED with |
| narrow-therapeutic index CYP2D6 substrates (specifically **Thioridazine**; pimozide). |
+---------------------------------------------------------------------------------------------------+
Atypical Antipsychotics: Olanzapine
Olanzapine is a thienobenzodiazepine second-generation antipsychotic with potent multi-receptor antagonism: blocks serotonin (5-HT2a, 5-HT2c, 5-HT3, 5-HT6), dopamine (D1, D2, D3, D4), histamine (H1), and alpha-1 adrenergic receptors.
- Pivotal Clinical Trial Evidence (Navari et al. NEJM 2016): In a Phase 3 randomized double-blind trial of patients receiving cisplatin or AC regimens, adding Olanzapine (10 mg PO daily on Days 1 to 4) to a 3-drug backbone (aprepitant + 5-HT3 RA + dexamethasone) significantly improved complete response (CR: no vomiting, no rescue):
- Acute Period (0–24h): CR 86% vs. 65% (p < 0.001)
- Delayed Period (24–120h): CR 67% vs. 52% (p = 0.007)
- Overall Period (0–120h): CR 64% vs. 41% (p < 0.001)
- Complete Nausea Prevention: CR 74% vs. 45% in the delayed phase.
- Dosing & Safety Optimization: Standard dose is 5 mg to 10 mg PO daily at bedtime on Days 1 to 4. In elderly patients (>=65–70 years) or frail individuals prone to sedation/falls, 5 mg PO daily is preferred and demonstrates equivalent antiemetic efficacy with significantly less next-day somnolence.
Corticosteroids: Dexamethasone
Dexamethasone is the most broadly active antiemetic, functioning through depletion of medullary GABA, suppression of peritumoral and gut prostaglandin synthesis, and reduction of blood-brain barrier permeability to emetogenic toxins.
- Dexamethasone Dosing Rules & CYP3A4 Adjustments:
- In regimens WITHOUT an NK1 RA: Dexamethasone 20 mg PO/IV on Day 1, then 8 mg PO BID (or 8 mg daily) on Days 2 to 4.
- In regimens WITH Aprepitant / Fosaprepitant / Netupitant (moderate CYP3A4 inhibitors): Dexamethasone 12 mg PO/IV on Day 1, then 8 mg PO daily on Days 2 to 4.
- In regimens WITH Rolapitant: Dexamethasone 20 mg Day 1, then 8 mg daily Days 2 to 4 (no CYP3A4 inhibition).
- Special Clinical Exceptions:
- When chemotherapy already includes high-dose systemic corticosteroids (e.g., Prednisone 100 mg in R-CHOP, Dexamethasone 40 mg in Hyper-CVAD), omit additional antiemetic dexamethasone.
- In patients receiving concurrent Immune Checkpoint Inhibitors (ICIs) or CAR T-cell therapies, short-course prophylactic antiemetic dexamethasone (1–3 days) does NOT impair immunotherapy efficacy and remains guideline-recommended for HEC/MEC.
4. Guideline-Directed Prophylactic Antiemetic Algorithms
+---------------------------------------------------------------------------------------------------+
| EVIDENCE-BASED CINV PROPHYLAXIS DECISION TREE (NCCN / ASCO) |
| |
| CHEMOTHERAPY REGIMEN ORDERED |
| | |
| +---------------------------+---------------------------+-------------------+ |
| | | | | |
| v v v v |
| [HIGH EMETIC RISK (HEC)] [MODERATE EMETIC RISK (MEC)] [LOW EMETIC RISK] [MINIMAL RISK] |
| (e.g., Cisplatin >=50, (e.g., Oxaliplatin, Irinotecan, (e.g., Taxanes, (e.g., MABs, |
| AC Breast Regimens) Cyclo <1500, Doxo <60) 5-FU, Gemcitabine) Vincas, Bleo) |
| | | | | |
| v v v v |
| **4-DRUG REGIMEN** +---+-------------------+ **1-DRUG REGIMEN** **NO ROUTINE** |
| (Category 1 Preferred) | | (Day 1 Only): **PROPHYLAXIS** |
| * Day 1: v v - Dexamethasone (Rescue available) |
| - Olanzapine 5-10 mg [CARBOPLATIN AUC >= 4] [OTHER MEC] 8 mg PO/IV OR |
| - NK1 RA (Aprepitant **3-DRUG REGIMEN** **2-3 DRUG REGIMEN**- 5-HT3 RA (Ondan |
| 125 mg / Fosaprep - NK1 RA (Day 1) - 5-HT3 RA (D1) 8 mg / Gran 1-2 mg) |
| 150 mg / NEPA) - 5-HT3 RA (Day 1) - Dexamethasone OR |
| - 5-HT3 RA (Palono - Dexamethasone (D1: 12 mg; - Prochlorperazine |
| 0.25 mg IV / Ondan) (D1: 12 mg; D2-3: 8 mg) 10 mg PO |
| - Dexamethasone 12 mg D2-3: none or 8 mg) +/- NK1 RA (optional) |
| * Days 2 to 4: +/- Olanzapine |
| - Olanzapine 5-10 mg |
| - Dexamethasone 8 mg |
| - Aprepitant 80 mg |
| (if oral used D1) |
+---------------------------------------------------------------------------------------------------+
Comprehensive Prophylactic Dosing Matrix
| Emetic Risk Category | Day 1 Prophylactic Regimen (Administered 30–60 min prior to Chemo) | Days 2 to 4 Post-Chemotherapy Regimen |
|---|---|---|
| High Emetic Risk (HEC)<br>(Cisplatin, AC, Dacarbazine, Mechlorethamine, Carmustine) | 4-Drug Regimen (Preferred Category 1):<br>• Olanzapine: 5–10 mg PO daily<br>• NK1 RA: Fosaprepitant 150 mg IV OR Aprepitant 125 mg PO OR NEPA (Netupitant 300 mg/Palono 0.5 mg PO)<br>• 5-HT3 RA: Palonosetron 0.25 mg IV OR Ondansetron 16 mg IV/24 mg PO<br>• Dexamethasone: 12 mg PO/IV (Day 1) | • Olanzapine: 5–10 mg PO daily on Days 2, 3, 4<br>• Dexamethasone: 8 mg PO daily on Days 2, 3, 4<br>• If oral Aprepitant used Day 1: Aprepitant: 80 mg PO daily on Days 2 and 3<br>(If Fosaprepitant or NEPA used on Day 1, no further NK1 dosing is required) |
| Moderate Emetic Risk (MEC)<br>Carboplatin AUC >= 4 | 3-Drug Regimen (Category 1):<br>• NK1 RA: Fosaprepitant 150 mg IV OR Aprepitant 125 mg PO OR NEPA<br>• 5-HT3 RA: Palonosetron 0.25 mg IV OR Ondansetron 8–16 mg IV<br>• Dexamethasone: 12 mg PO/IV | • If oral Aprepitant used: Aprepitant: 80 mg PO daily on Days 2 and 3<br>• Dexamethasone: 8 mg PO daily on Days 2 and 3 (optional if Palonosetron + NK1 used) |
| Moderate Emetic Risk (MEC)<br>(Oxaliplatin, Irinotecan, Cyclophosphamide <1500) | 2-Drug Regimen:<br>• 5-HT3 RA: Palonosetron 0.25 mg IV OR Ondansetron 8–16 mg IV<br>• Dexamethasone: 12 mg PO/IV<br>(May add NK1 RA or Olanzapine for patients with additional risk factors) | • Dexamethasone: 8 mg PO daily on Days 2 and 3 (OR 5-HT3 RA daily Days 2–3 if first-generation 5-HT3 used on Day 1)<br>(No delayed therapy needed if Palonosetron 0.25 mg IV used Day 1) |
| Low Emetic Risk<br>(Taxanes, Gemcitabine, 5-FU, Methotrexate) | Single-Agent Regimen (Choose one on Day 1):<br>• Dexamethasone: 8 mg PO/IV OR<br>• Ondansetron: 8 mg PO/IV OR Granisetron 1–2 mg PO OR<br>• Prochlorperazine: 10 mg PO/IV OR Metoclopramide 10–20 mg PO | None (No routine post-chemotherapy prophylaxis; provide as-needed breakthrough antiemetic prescription) |
| Minimal Emetic Risk<br>(Monoclonals, Vincristine, Bleomycin) | No routine pre-medication (unless required for infusion reaction prophylaxis, e.g., rituximab) | None |
5. Multi-Day Chemotherapy & Breakthrough CINV Management
Multi-Day Chemotherapy Protocols (e.g., Cisplatin Days 1–5 in BEP / EP)
- Patients receiving multi-day cisplatin or ifosfamide experience overlapping acute and delayed emetic stimuli.
- Guideline Strategy:
- Administer a 5-HT3 RA daily prior to each day's chemotherapy dose (or Palonosetron on Days 1, 3, and 5).
- Administer Dexamethasone daily on chemotherapy days (12–20 mg/day) and continue for 2–3 days following the final chemotherapy day (8 mg daily).
- Administer an NK1 RA: Aprepitant 125 mg on Day 1, then 80 mg daily on Days 2 to 5 (or Fosaprepitant 150 mg IV Day 1 and Day 3).
- Co-prescribe Olanzapine 5–10 mg PO daily on Days 1 through the final day of chemotherapy plus 2–3 days post-chemo.
Breakthrough CINV Interception Algorithm
When breakthrough nausea or emesis occurs despite guideline-directed prophylaxis, the primary rule is: NEVER escalate the dose of the failing drug class; ADD a new agent from an unutilized pharmacologic class with a distinct mechanism of action.
+---------------------------------------------------------------------------------------------------+
| BREAKTHROUGH CINV PHARMACOTHERAPY MATRIX |
| |
| 1. OLANZAPINE (if not utilized in baseline prophylaxis): |
| - Dose: **5 mg to 10 mg PO daily x 3 days** at bedtime (Category 1 preferred rescue). |
| |
| 2. PHENOTHIAZINES / DOPAMINE ANTAGONISTS: |
| - **Prochlorperazine (Compazine):** 10 mg PO/IV/PR every 4 to 6 hours PRN (max 40 mg/day). |
| - **Promethazine (Phenergan):** 12.5 to 25 mg PO/PR/deep IM every 4 to 6 hours PRN. |
| * BLACK BOX WARNING: Severe chemical phlebitis / tissue gangrene on IV extravasation. |
| |
| 3. BENZAMIDES (Prokinetic / D2 + 5-HT4 agonist / 5-HT3 antagonist): |
| - **Metoclopramide (Reglan):** 10 to 20 mg PO/IV every 6 hours PRN. |
| - Excellent for gastroparesis / postprandial fullness. |
| - Black Box Warning: Tardive dyskinesia / extrapyramidal symptoms (EPS) with prolonged use. |
| |
| 4. BUTYROPHENONES: |
| - **Haloperidol:** 0.5 to 2 mg PO/IV every 4 to 6 hours PRN. |
| |
| 5. CANNABINOIDS: |
| - **Dronabinol (Marinol):** 2.5 to 10 mg PO every 4 to 6 hours PRN (CB1 receptor agonist). |
| |
| 6. BENZODIAZEPINES: |
| - **Lorazepam (Ativan):** 0.5 to 2 mg PO/IV every 4 to 6 hours PRN (anxiolytic / amnesic). |
| |
| * EXTRA-PYRAMIDAL SYMPTOM (EPS) ANTIDOTE: |
| If acute dystonia or oculogyric crisis occurs from dopamine antagonists (prochlorperazine, |
| metoclopramide), administer **Diphenhydramine 25 to 50 mg IV** or **Benztropine 1 to 2 mg IV**|
+---------------------------------------------------------------------------------------------------+
A 48-year-old female with newly diagnosed Stage IIB triple-negative breast cancer is initiating adjuvant dose-dense AC chemotherapy (Doxorubicin 60 mg/m2 IV plus Cyclophosphamide 600 mg/m2 IV every 14 days). She has a history of severe motion sickness and emesis during past pregnancies. The medical oncology fellow enters the following antiemetic prophylaxis orders: Ondansetron 8 mg IV once on Day 1 and Dexamethasone 12 mg IV once on Day 1. As the board-certified oncology pharmacist conducting regimen verification, which recommendation is most appropriate based on consensus CINV guidelines?
A 64-year-old male with recurrent non-small cell lung cancer is receiving systemic therapy with Carboplatin (target AUC = 6) plus Pemetrexed (500 mg/m2) on Day 1 every 21 days. The clinical pharmacist is selecting the optimal antiemetic regimen. In accordance with updated ASCO and NCCN antiemetic guidelines, what is the most appropriate prophylactic antiemetic strategy for this patient's carboplatin regimen?
A 56-year-old female with metastatic colorectal cancer is receiving FOLFOXIRI (5-Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan). On Day 1, she receives Palonosetron 0.25 mg IV and Dexamethasone 12 mg IV. On Day 3 at home, she contacts the oncology triage line reporting persistent moderate nausea and three episodes of vomiting over the past 8 hours despite taking oral ondansetron 8 mg every 8 hours. She has not received olanzapine or prochlorperazine. What is the most appropriate pharmacotherapeutic recommendation for breakthrough CINV in this patient?
A clinical oncology pharmacist is conducting an order verification review for an oral antiemetic regimen containing Aprepitant (125 mg PO Day 1, 80 mg PO Days 2–3) and co-prescribed oral Dexamethasone for a patient receiving high-dose cisplatin (75 mg/m2). The ordering physician asks why the dexamethasone dose was reduced from the institutional default of 20 mg to 12 mg on Day 1, and from 16 mg to 8 mg daily on Days 2 through 4. Which pharmacological explanation is correct?